The University of Missouri System, doing business as Curators of the University of Missouri, received a $658,885 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to research the molecular mechanisms by which Response Gene to Complement 32 (RGC-32) regulates endothelial-mesenchymal transition (EndoMT) in pulmonary artery endothelial cells and its role in the development of pulmonary arterial hypertension (PAH). The 4-year grant, awarded on January 1, 2025, will leverage in vitro cell studies and in vivo animal models to determine how RGC-32 promotes PAH progression through facilitating EndoMT. The research aims to establish RGC-32 as a novel therapeutic target to combat this rapidly progressive and currently incurable cardiovascular disease.
Generated 2/25/25, 4:31 AM